Korean Circulation Journal

Papers
(The H4-Index of Korean Circulation Journal is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Beyond Biventricular Pacing: Revisiting CRT Strategies in the Asian Heart Failure Population64
Gender Is Not Predictor for Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Coronary Bifurcation46
Association Between Body Mass Index and Clinical Outcomes According to Diabetes in Patients Who Underwent Percutaneous Coronary Intervention36
Proteomic Dissection of Aortic Stenosis: Distinct VIC Signatures and the Role of Aging in Valve Remodeling28
The Emerging Lipid Risk: Lipoprotein(a)24
Strategy of Patient-Specific Therapeutics in Cardiovascular Disease Through Single-Cell RNA Sequencing23
Seven-day and In-hospital Mortality According to Left and Right Ventricular Dysfunction in Patients With Septic Shock23
Comparison of Thick Biolimus A9-Eluting Stent and Thin Zotarolimus-Eluting Stent in Multi-Vessel Percutaneous Coronary Intervention23
Volume in Targeted Temperature Management Reflects System-Level Quality Rather Than Treatment Effect23
The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health20
Will Cryoballoon Ablation Cool Down Atrial Fibrillation in Korea?19
Epigenetic Modulation in Heart Failure: HDAC Inhibitors as Emerging Therapeutic Allies19
Arterial Inflow Strategy in Acute Type A Aortic Dissection: Cannulation as a Component of an Integrated Arch Repair Philosophy18
Deep Learning-Based Intravascular Ultrasound Images Segmentation in Coronary Artery Disease: A Start Developing the Cornerstone18
Mitochondrial Integrity as the Gatekeeper of Cardiac Stress Adaptation: Insights From CRIF1 Deficiency16
Early Initiation of Evolocumab in Patients With Acute Coronary Syndrome16
Age-Dependent Role of Genetics and Renal Function for Atrial Fibrillation Development in Hypertrophic Cardiomyopathy16
0.32719492912292